View Filing Data

Print Document View Excel Document

Cover Page - shares	6 Months Ended
Cover Page - shares	Jun. 30, 2020	Jul. 24, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2020
Document Transition Report	false
Entity File Number	001-33137
Entity Registrant Name	EMERGENT BIOSOLUTIONS INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	14-1902018
Entity Address, Address Line One	400 Professional Drive Suite 400
Entity Address, City or Town	Gaithersburg,
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20879
City Area Code	240
Local Phone Number	631-3200
Title of 12(b) Security	Common Stock, Par Value $0.001 per share
Trading Symbol	EBS
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		52,924,889
Entity Central Index Key	0001367644
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 268.8	$ 167.8
Restricted cash	0.2	0.2
Accounts receivable, net	258.6	270.7
Inventories	236.2	222.5
Prepaid expenses and other current assets	32.1	25.0
Total current assets	795.9	686.2
Property, plant and equipment, net	580.1	542.3
Intangible assets, net	693.2	712.9
In-process research and development	29.0	29.0
Goodwill	266.3	266.6
Other assets	101.6	90.3
Total assets	2,466.1	2,327.3
Current liabilities:
Accounts payable	84.8	94.8
Accrued expenses	33.8	39.5
Debt, current portion	59.0	62.4
Debt, current portion	29.1	12.9
Contract liabilities, current portion	32.7	3.3
Business Combination, Contingent Consideration, Liability, Current	22.3	3.2
Other current liabilities	32.0	0.2
Total current liabilities	293.7	216.3
Contingent consideration, net of current portion	6.9	26.0
Debt, net of current portion	758.1	798.4
Deferred tax liability	63.9	63.9
Contract liabilities, net of current portion	85.3	85.6
Other liabilities	59.4	48.6
Total liabilities	1,267.3	1,238.8
Stockholders' equity:
Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding	0.0	0.0
Common stock, $0.001 par value; 200.0 shares authorized, 54.1 and 52.9 shares issued; 52.9 and 51.7 shares outstanding, respectively	0.1	0.1
Treasury stock, at cost, 1.2 common shares	(39.6)	(39.6)
Additional paid-in capital	758.5	716.1
Accumulated other comprehensive loss, net	(22.2)	(9.9)
Retained earnings	502.0	421.8
Total stockholders' equity	1,198.8	1,088.5
Total liabilities and stockholders' equity	$ 2,466.1	$ 2,327.3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	15,000,000.0	15,000,000.0
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000.0	200,000,000.0
Common stock, shares issued (in shares)	54,100,000	53,000,000
Common stock, shares outstanding (in shares)	52,900,000	51,700,000
Treasury stock (in shares)	1,200,000	1,200,000

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues:
Total revenues	$ 394.7	$ 243.2	$ 587.2	$ 433.9
Operating expenses:
Cost of product sales and contract development and manufacturing services	129.8	100.8	206.7	192.7
Research and development	47.9	63.9	90.6	110.0
Selling, general and administrative	76.0	70.8	145.7	136.4
Amortization of intangible assets	15.0	14.7	29.8	29.2
Total operating expenses	268.7	250.2	472.8	468.3
Income (loss) from operations	126.0	(7.0)	114.4	(34.4)
Other income (expense):
Interest expense	(6.4)	(9.5)	(15.0)	(19.0)
Other, net	1.1	1.4	0.0	0.4
Total other income (expense), net	(5.3)	(8.1)	(15.0)	(18.6)
Income (loss) before provision for income taxes	120.7	(15.1)	99.4	(53.0)
Income tax provision (benefit)	28.0	(5.6)	19.2	(17.4)
Net income (loss)	$ 92.7	$ (9.5)	$ 80.2	$ (35.6)
Net income (loss) per common share
Basic (in dollars per share)	$ 1.76	$ (0.18)	$ 1.53	$ (0.69)
Diluted (in dollars per share)	$ 1.73	$ (0.18)	$ 1.51	$ (0.69)
Shares used in computing income (loss) per share
Basic (in shares)	52.6	51.5	52.3	51.3
Diluted (in shares)	53.5	51.5	53.2	51.3
Product sales, net
Revenues:
Total revenues	$ 298.5	$ 183.5	$ 446.7	$ 336.5
Contract development and manufacturing services
Revenues:
Total revenues	72.6	18.7	94.3	34.6
Contracts and grants
Revenues:
Total revenues	$ 23.6	$ 41.0	$ 46.2	$ 62.8

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 92.7	$ (9.5)	$ 80.2	$ (35.6)
Other comprehensive (loss) income, net of tax:
Foreign currency translation	(0.3)	0.7	(0.4)	1.7
Unrealized losses on hedging activities	(0.7)	(1.2)	(11.9)	(1.2)
Total other comprehensive (loss) income	(1.0)	(0.5)	(12.3)	0.5
Comprehensive income (loss)	$ 91.7	$ (10.0)	$ 67.9	$ (35.1)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Unrealized losses on hedging activities	$ 0.8	$ 0.0	$ 3.6	$ 0.0
Unrealized losses related to foreign currency translations	$ 0.0	$ 0.0	$ 0.0	$ 0.0

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows provided by operating activities:
Net income (loss)	$ 80.2	$ (35.6)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation expense	31.0	14.9
Depreciation and amortization	56.8	55.1
Amortization of deferred financing costs	1.5	1.5
Deferred income taxes	(3.7)	(1.3)
Change in fair value of contingent consideration, net	1.1	5.5
Other	1.1	2.9
Changes in operating assets and liabilities:
Accounts receivable	12.1	44.6
Inventories	(13.7)	(26.1)
Prepaid expenses and other assets	(16.9)	(44.9)
Accounts payable	(14.5)	42.6
Accrued expenses	25.0	6.9
Accrued compensation	(3.4)	(13.5)
Contract liabilities	29.1	16.4
Net cash provided by operating activities:	185.7	69.0
Cash flows used in investing activities:
Purchases of property, plant and equipment and other	(59.3)	(35.5)
Milestone payment from prior asset acquisition	(10.0)	(10.0)
Net cash used in investing activities:	(69.3)	(45.5)
Cash flows (used in) provided by financing activities:
Proceeds from revolving credit facility	0.0	130.0
Principal payments on revolving credit facility	(20.0)	(80.0)
Principal payments on term loan facility	(5.6)	(5.6)
Proceeds from exercise of stock options	23.1	4.6
Taxes paid for share-based compensation activity	(11.7)	(6.3)
Contingent consideration payments	(1.1)	(1.0)
Net cash (used in) provided by financing activities:	(15.3)	41.7
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(0.1)	0.0
Net increase in cash, cash equivalents and restricted cash	101.0	65.2
Cash, cash equivalents and restricted cash at beginning of period	168.0	112.4
Cash, cash equivalents and restricted cash at end of period	269.0	177.6
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	11.6	18.3
Cash paid during the period for income taxes	12.2	13.4
Supplemental information on non-cash investing and financing activities:
Purchases of property, plant and equipment unpaid at period end	16.8	11.4
Reconciliation of cash and cash equivalent and restricted cash
Total cash, cash equivalents and restricted cash	$ 269.0	$ 177.6

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Millions	Total	$0.001 Par Value Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Other Comprehensive Loss	Retained Earnings
Balance (in shares) at Dec. 31, 2018		52,400,000		1,200,000
Balance at Dec. 31, 2018	$ 1,010.9	$ 0.1	$ 688.6	$ (39.6)	$ (5.5)	$ 367.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee equity plans activity (in shares)		300,000
Employee equity plans activity	13.1		13.2	$ (0.1)
Net income (loss)	(35.6)					(35.6)
Other comprehensive income	0.5				0.5
Balance (in shares) at Jun. 30, 2019		52,700,000		1,200,000
Balance at Jun. 30, 2019	988.9	$ 0.1	701.8	$ (39.7)	(5.0)	331.7
Balance (in shares) at Mar. 31, 2019		52,600,000		1,200,000
Balance at Mar. 31, 2019	987.3	$ 0.1	690.1	$ (39.6)	(4.5)	341.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee equity plans activity (in shares)		100,000
Employee equity plans activity	11.6		11.7	$ (0.1)
Net income (loss)	(9.5)					(9.5)
Other comprehensive income	(0.5)				(0.5)
Balance (in shares) at Jun. 30, 2019		52,700,000		1,200,000
Balance at Jun. 30, 2019	$ 988.9	$ 0.1	701.8	$ (39.7)	(5.0)	331.7
Balance (in shares) at Dec. 31, 2019	53,000,000	53,000,000.0		1,200,000
Balance at Dec. 31, 2019	$ 1,088.5	$ 0.1	716.1	$ (39.6)	(9.9)	421.8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee equity plans activity (in shares)		1,100,000
Employee equity plans activity	42.4		42.4	$ 0.0
Net income (loss)	80.2					80.2
Other comprehensive income	$ (12.3)				(12.3)
Balance (in shares) at Jun. 30, 2020	54,100,000	54,100,000		1,200,000
Balance at Jun. 30, 2020	$ 1,198.8	$ 0.1	758.5	$ (39.6)	(22.2)	502.0
Balance (in shares) at Mar. 31, 2020		53,500,000		1,200,000
Balance at Mar. 31, 2020	1,074.8	$ 0.1	726.2	$ (39.6)	(21.2)	409.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee equity plans activity (in shares)		600,000
Employee equity plans activity	32.3		32.3	$ 0.0
Net income (loss)	92.7					92.7
Other comprehensive income	$ (1.0)				(1.0)
Balance (in shares) at Jun. 30, 2020	54,100,000	54,100,000		1,200,000
Balance at Jun. 30, 2020	$ 1,198.8	$ 0.1	$ 758.5	$ (39.6)	$ (22.2)	$ 502.0

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Statement of Stockholders' Equity [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001

Business

6 Months Ended

Jun. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business

Organization and business

Emergent BioSolutions Inc. (the "Company" or "Emergent") is a global life sciences company focused on providing civilian and military populations a portfolio of innovative preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats ("PHTs," each a “PHT”).

The Company is focused on the following five distinct PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives ("CBRNE"); emerging infectious diseases ("EID"); travel health; emerging health crises; acute/emergency care; and contract development and manufacturing ("CDMO"). The Company has a product portfolio of ten products (vaccines, therapeutics, and drug-device combination products) that contribute a substantial portion of our revenue. The Company has two product candidates that are procured under special circumstances by certain government agencies, although they are not approved by the U.S. Food and Drug Administration ("FDA") or any health agency. The U.S. government (the "USG") is the Company's largest customer and provides the Company with substantial funding for the development of a number of its product candidates.

The Company's product and services portfolio includes:

Vaccines


▪	ACAM2000^® (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;


▪	BioThrax^® (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA, for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;


▪	Vaxchora® (Cholera Vaccine, Live, Oral), the only vaccine licensed by the FDA and the European Medicines Agency (EUA) for the prevention of cholera; and


▪	Vivotif® (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever.

Devices


▪	NARCAN® (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression; and


▪	RSDL^® (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin.

Therapeutics


▪	raxibacumab (Anthrax Monoclonal), a fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;


▪	Anthrasil^® (Anthrax Immune Globulin Intravenous (Human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;


▪	BAT® (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antibody therapeutic licensed by the FDA and Health Canada for the treatment of botulism; and


▪	VIGIV (Vaccinia Immune Globulin Intravenous (Human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination.

Procured Product Candidates

•

AV7909^®(Anthrax Vaccine Absorbed with Adjuvant), is a procured product candidate being developed as a next generation anthrax vaccine for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure. The USG has started procuring AV7909 for the Strategic National Stockpile ("SNS") prior to its approval by the FDA and has been reducing its purchases of BioThrax as a result; and


•	Trobigard® is a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA or any similar health regulatory body, but it is

procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure.

Contract Development and Manufacturing Services

The Company's contract development and manufacturing service offerings cover development services, drug substance manufacturing and drug product manufacturing across the pharmaceutical and biotechnology industries as well as the USG and non-governmental organizations. The Company's technology platforms include mammalian, microbial, viral, plasma and advanced therapies utilizing our core capabilities for manufacturing to third parties on a clinical and commercial (small and large) scale. Additional services include fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats multiple platforms.

The Company operates as one operating segment.

Basis of Presentation and Principles of Consolidation	6 Months Ended
Basis of Presentation and Principles of Consolidation	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation Basis of presentation The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC. All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of June 30, 2020. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year. Significant accounting policies During the six months ended June 30, 2020, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC. During the six months ended June 30, 2020, the Company entered into several multi-year CDMO arrangements and further defined our accounting policies around these arrangements in Note 10. Fair value measurements Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7 and Note 8). As of June 30, 2020 and December 31, 2019, the Company held cash in money market accounts of $178.7 million and $52.2 million, respectively. The Company also records the assets and liabilities of acquisitions at fair value. On a non-recurring basis, the Company measures its long-lived assets, including IPR&D assets (level 3) using fair value measurements. Goodwill is allocated to the Company's reporting units, which are one level below its operating segment. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October 1 and earlier if an event or other circumstance indicates that we may not recover the carrying value of the asset. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required. Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, long-lived assets are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when there is an adverse change in the market relating to those related assets. The impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. Determining the need for a detailed impairment analysis requires the exercise of judgment about several business factors, including the timing of expected future cash flows and assumptions about the economic environment. During the three and six months ended June 30, 2020, the Company observed a decrease in sales related to its travel health vaccines and the increased risk of generic competition related to NARCAN® Nasal Spray. However, we do not believe that there is a long-term decrease in the expected cash flows of our reporting units that include goodwill or our long-lived asset groups such that our assets are not recoverable or that their carrying value is greater than their fair value as of June 30, 2020. As of June 30, 2020 and December 31, 2019, the Company had no other significant assets or liabilities that were measured at fair value. Recently issued accounting standards Recently Adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13") In June 2016, the FASB issued ASU 2016-13. ASU 2016-13 provides guidance on measurement of credit losses on financial instruments that changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans, and that requires entities to use a new, forward-looking “expected loss” model that is expected to generally result in the earlier recognition of allowances for losses. The guidance became effective for annual periods beginning after December 15, 2019, including interim periods within those years. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company's consolidated financial statements. ASU 2018-13, Fair Value Measurement - Disclosure Framework (Topic 820) ("ASU 2018-13") In August 2018, the FASB issued ASU 2018-13. ASU 2018-13 improves the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any removed or modified disclosures. The Company adopted the standard as of January 1, 2020 which has resulted in expanded disclosures around the Company's recurring level 3 fair value measurements. The disclosures are included in note 7 of the condensed consolidated financial statements. ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15") In August 2018, the FASB issued ASU 2018-15. ASU 2018-15 clarifies the accounting for implementation costs in cloud computing arrangements. ASU 2018-15 is effective for all entities for fiscal years beginning after December 15, 2019. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company's consolidated financial statements. ASU 2017-4, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-4") In January 2017, the FASB issued ASU 2017-4. ASU 2017-4 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-4 is effective for annual and interim goodwill tests beginning after December 15, 2019. The Company's measurement period is October 1. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption will not have a material impact on the Company's consolidation financial statements. Not Yet Adopted ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting In March 2020, the FASB issued Topic 848. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. ASC 848 contains optional expedients and exceptions for applying US GAAP to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. The Company continues to assess all potential impacts of the standard and will disclose the nature and reason for any elections that the Company makes. ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans ("ASU 2018-14") In August 2018, the FASB issued ASU 2018-14. ASU 2018-14 modifies the disclosure requirements for defined benefit pension plans and other post-retirement plans. ASU 2018-14 is effective for all entities for fiscal years ending after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-14 on its consolidated financial statements. ASU 2019-12, Simplifications to Accounting for Income Taxes ("ASU 2019-12") In December 2019, the FASB issued ASU 2019-12. ASU 2019-12 removes certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including deferred taxes for goodwill and allocating taxes for members of a consolidated group. ASU 2019-12 is effective for all entities for fiscal years beginning after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12 on its consolidated financial statements.

Inventories

6 Months Ended

Jun. 30, 2020

Inventory Disclosure [Abstract]

Inventories

The components of inventory are as follows:



	June 30, 2020		December 31, 2019
Raw materials and supplies	$	81.7	$	70.5
Work-in-process	117.1		89.7
Finished goods	37.4		62.3
Total inventories	$	236.2	$	222.5

Property, plant and equipment

6 Months Ended

Jun. 30, 2020

Property Plant and Equipment Income Statement Disclosures [Abstract]

Property, plant and equipment

Property, plant and equipment consisted of the following:



	June 30, 2020			December 31, 2019
Land and improvements	$	50.2		$	46.5
Buildings, building improvements and leasehold improvements	253.0			234.8
Furniture and equipment	342.6			334.2
Software	56.0			55.7
Construction-in-progress	112.7			81.5
Property, plant and equipment, gross	814.5			752.7
Accumulated depreciation	(234.4		)	(210.4		)
Total property, plant and equipment, net	$	580.1		$	542.3

Leases

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Leases

The Company has operating leases for corporate offices, research and development facilities and manufacturing facilities. We determine if an arrangement is a lease at inception. Operating leases are included in right-of-use ("ROU") assets and liabilities.

ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options.

Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately. The Company's leases have remaining lease terms of 1 year to 15 years, some of which include options to extend the leases for up to 5 years, and some of which include options to terminate the leases within 1 year.

The components of lease expense were as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Operating lease cost:
Amortization of right-of-use assets	$	1.0	$	0.7	$	2.1	$	1.3
Interest on lease liabilities	0.3		0.2		0.6		0.3
Total operating lease cost	$	1.3	$	0.9	$	2.7	$	1.6

Supplemental balance sheet information related to leases was as follows:



(In millions, except lease term and discount rate)	Balance Sheet location	June 30, 2020			December 31, 2019
Operating lease right-of-use assets	Other assets	$	24.5		$	24.7

Operating lease liabilities, current portion	Other current liabilities	4.5			3.6
Operating lease liabilities	Other liabilities	21.6			22.1
Total operating lease liabilities		$	26.1		$	25.7

Operating leases:
Weighted average remaining lease term (years)		7.5			8.0
Weighted average discount rate		4.2		%	4.2		%

Intangible assets

6 Months Ended

Jun. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangible assets

The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. The following tables summarize the Company's intangible assets for the periods ended June 30, 2020 and December 31, 2019:



		June 30, 2020
(in millions)	Estimated Life	Cost		Additions		Accumulated Amortization		Net
Products	9-22 years	$	788.0	$	10.0	$	109.8	$	688.2
Customer relationships	8 years	28.6		—		24.7		3.9
Contract development and manufacturing	8 years	5.5		—		4.4		1.1
Total intangible assets		$	822.1	$	10.0	$	138.9	$	693.2



		December 31, 2019
(in millions)	Estimated Life	Cost		Accumulated Amortization		Net
Products	9-22 years	$	788.0	$	82.2	$	705.8
Customer relationships	8 years	28.6		23.0		$	5.6
Contract development and manufacturing	8 years	5.5		4.0		$	1.5
Total intangible assets		$	822.1	$	109.2	$	712.9

During the six months ended June 30, 2020 and 2019, the Company achieved a sales milestone that resulted in a $10.0 million obligation related to the Company's asset acquisition of raxibacumab in October 2017. As of June 30, 2020 there are no remaining contractual obligations for sales milestones related to the raxibacumab acquisition.

During the six months ended June 30, 2020 and 2019, the Company recorded amortization expense for intangible assets of $29.8 million and $29.2 million, respectively. During the three months ended June 30, 2020 and 2019, the Company recorded amortization expense for intangible assets of $15.0 million and $14.7 million, respectively. As of June 30, 2020, the weighted average amortization period remaining for intangible assets was 13 years.

In-process research and development ("IPR&D") assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. There were no changes to the Company's IPR&D assets during the six months ended June 30, 2020.

Goodwill was $266.3 million and $266.6 million for the periods ended June 30, 2020 and December 31, 2019, respectively. The change in the balance during the period was due to foreign currency translation adjustments.

Contingent consideration

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Contingent Consideration

Contingent consideration

Contingent consideration liabilities associated with business combinations are measured at fair value. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market (Level 3).

The following table is a reconciliation of the beginning and ending balance of contingent considerations and is based on level 3 significant unobservable inputs.




Balance at December 31, 2019	$	29.2
Change in fair value	1.1
Settlements	(1.1		)
Balance at June 30, 2020	$	29.2

The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs:



Contingent Consideration Liability	Fair Value as of June 30, 2020	Valuation Technique	Unobservable Input	Range	Weighted Average
Revenue milestone and royalty based	$29.2 million	Discounted cash flow	Discount rate	2.5% - 8.6%	4.3%
			Probability of payment	10.0% - 40.0%	20.9%
			Projected year of payment	2020 - 2028	2022

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Derivative instruments and hedging activities

6 Months Ended

Jun. 30, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure

Derivative instruments and hedging activities

Risk management objective of using derivatives

The Company is exposed to certain risk arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from the Company's senior secured credit agreement's payments of variable interest rate debt.

Accounting policy for derivative instruments and hedging activities

The Company entered into interest rate swaps in June 2019. The Company's interest rate swaps qualify for hedge accounting as cash flow hedges. All derivatives are recorded on the balance sheet at fair value. Hedge accounting provides for the matching of the timing of gain or loss recognition on these interest rate swaps with the recognition of the changes in interest expense on the Company's variable rate debt. For derivatives designated as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings. Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. The cash flows from the designated interest rate swaps are classified as a component of operating cash flows, similar to interest expense. If current fair values of designated interest rate swaps remained static over the next twelve months, the Company would reclassify $5.7 million of net deferred losses from accumulated other comprehensive loss to the statement of operations over the next twelve month period. All outstanding cash flow hedges mature in October 2023.

As of June 30, 2020, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:



	Number of Instruments	Notional
Interest rate swaps	7	$	350.0

The table below presents the fair value of the Company’s derivative financial instruments designated as hedges as well as their classification on the balance sheet.



Asset Derivatives							Liability Derivatives
	June 30, 2020			December 31, 2019			June 30, 2020			December 31, 2019
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Interest Rate Swaps	Other Current Assets	$	—	Other Current Assets	$	—	Other Current Liabilities	$	5.6	Other Current Liabilities	$	—
Interest Rate Swaps	Other Assets	$	—	Other Assets	$	—	Other Liabilities	$	11.9	Other Liabilities	$	2.0

The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. To comply with the provisions of ASC 820, Fair Value Measurement, we incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk. These credit valuation adjustments were concluded to not be significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.

The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income.



Hedging derivatives	Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative					Location of Gain or (Loss) Reclassified from Accumulated OCI into Income	Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income
Hedging derivatives	June 30,			December 31,			Six Months Ended June 30,
	2020			2019			2020			2019
Interest Rate Swaps	$	(17.5	)	$	2.0	Interest expense	$	(1.1	)	$	—

Debt

6 Months Ended

Jun. 30, 2020

Debt Disclosure [Abstract]

Debt

The components of debt are as follows:



	June 30, 2020			December 31, 2019
Senior secured credit agreement - Term loan due 2023	$	430.3		$	435.9
Senior secured credit agreement - Revolver loan due 2023	353.0			373.0
2.875% Convertible Senior Notes due 2021	10.6			10.6
Other	3.0			3.0
Total debt	796.9			822.5
Current portion of long-term debt, net of debt issuance costs	(29.1		)	(12.9		)
Unamortized debt issuance costs	(9.7		)	(11.2		)
Non-current portion of debt	$	758.1		$	798.4

Senior secured credit agreement

In October 2018, the Company entered into a senior secured credit agreement with multiple lending institutions (the "Credit Agreement"). The terms of the credit agreement include (i) a revolving credit facility (the "Revolving Credit Facility") of $600 million with a maturity date of October 13, 2023, and (ii) a term loan with a principal amount of $450 million (the "Term Loan Facility," and together with the Revolving Credit Facility, the "Senior Secured Credit Facilities"). The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") as long as requirements relating to net leverage ratio will be maintained on a pro forma basis.

Borrowings under the Revolving Credit Facility and the Term Loan Facility will bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from 1.25% to 2.00% per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus 0.50%, and a eurocurrency rate for an interest period of one month plus 1% plus a margin ranging from 0.25% to 1.00%, depending on the Company's consolidated net leverage ratio. The Company is required to make quarterly payments under the Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from 0.15% to 0.30% per annum, depending on the Company's consolidated net leverage ratio, in respect of the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments based on an annual percentage equal to 2.5% of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, 5% of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and 7.5% of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature (unless earlier terminated) on October 13, 2023.

The Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Credit Agreement or (b) receive cash proceeds in excess of $100 million during the term of the Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.

The financial covenants under the Credit Agreement currently require the quarterly presentation of a minimum consolidated 12-month rolling debt service coverage ratio of 2.50 to 1.00, and a maximum consolidated net leverage ratio of 3.75 to 1.00 for the quarterly filing periods from October 1, 2019 through September 29, 2020 and 3.50 to 1.0, thereafter, which may be adjusted to 4.00 to 1.00 for a four quarter period in connection with a material permitted acquisition. Negative covenants in the Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments. As of the date of these financial statements, the Company is in compliance with all affirmative and negative covenants.

2.875% Convertible senior notes due 2021

On January 29, 2014, the Company issued 2.875% convertible senior notes due 2021 (the "Notes"). The Notes bear interest at a rate of 2.875% per year, payable semi-annually in arrears on January 15 and July 15 of each year. The Notes mature on January 15, 2021.

Revenue recognition

6 Months Ended

Jun. 30, 2020

Revenue from Contract with Customer [Abstract]

Revenue recognition

The Company operates as one operating segment. Therefore, results of its operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. The Company's revenues disaggregated by the major sources were as follows:



	Three Months Ended June 30, 2020						Three Months Ended June 30, 2019
	U.S. Government		Non-U.S. Government		Total		U.S. Government		Non-U.S. Government		Total
Product sales, net	$	224.2	$	74.3	$	298.5	$	94.6	$	88.9	$	183.5
Contract development and manufacturing services	44.6		28.0		72.6		—		18.7		18.7
Contracts and grants	20.7		2.9		23.6		38.3		2.7		41.0
Total revenues	$	289.5	$	105.2	$	394.7	$	132.9	$	110.3	$	243.2

	Six Months Ended June 30, 2020						Six Months Ended June 30, 2019
	U.S. Government		Non-U.S. Government		Total		U.S. Government		Non-U.S. Government		Total
Product sales, net	$	288.1	$	158.6	$	446.7	$	167.9	$	168.6	$	336.5
Contract development and manufacturing services	44.6		49.7		94.3		—		34.6		34.6
Contracts and grants	42.7		3.5		46.2		58.7		4.1		62.8
Total revenues	$	375.4	$	211.8	$	587.2	$	226.6	$	207.3	$	433.9

Contract liabilities

When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the consolidated balance sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the rollforward of the contract liability balances:




December 31, 2019	$	88.9
Deferral of revenue	56.3
Revenue recognized	(27.2		)
June 30, 2020	$	118.0

Transaction price allocated to remaining performance obligations

During the three and six months ended June 30, 2020, the Company entered into a number of multi-year contract development and manufacturing services arrangements for the production of developmental vaccines. The Company's performance obligations associated with these arrangements include multiple performance obligations such as technology transfer activities, stand-ready obligations and drug substance manufacturing. The Company has determined that the technology transfer and stand-ready performance obligations are satisfied over time, while the drug substance manufacturing performance obligations are satisfied at a point in time when the goods have been released, legal title has passed and the goods are in the customer's possession.

As of June 30, 2020, the Company expects future revenues of approximately $1.4 billion associated with all performance obligations that have not been satisfied, including the new arrangements referenced in the previous paragraph. The Company expects to recognize a majority of these revenues within the next 24 months. However, the amount and timing of revenue recognition for unsatisfied performance obligations can materially change due to timing of funding appropriations from the USG and the overall success of the Company's development activities associated with its PHT procured product candidates that are then receiving development funding support from the USG under development contracts. In addition, the amount of future revenues associated with unsatisfied performance obligations excludes the value associated with unexercised option periods in the Company's contracts.

Contract assets

The Company considers unbilled accounts receivables and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment, as contract assets. As of June 30, 2020 and December 31, 2019, the Company had contract assets associated with deferred costs of $40.6 million and $34.0 million, respectively, which is reflected as a component of other assets on the Company's consolidated balance sheets.

Accounts receivable

Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:



	June 30, 2020		December 31, 2019
Billed, net	$	202.2	$	227.3
Unbilled	56.4		43.4
Total, net	$	258.6	$	270.7

As of June 30, 2020 and December 31, 2019, allowances for doubtful accounts were $0.5 million and de minimis, respectively.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Income taxes	6 Months Ended
Income taxes	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income taxes	Income taxes On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company has assessed the impact of the CARES Act and we do not expect there to be a material impact to our consolidated financial statements. The estimated effective annual tax rate for the Company, which excludes discrete adjustments, was 26% and 27% for the six months ended June 30, 2020 and 2019. For the six months ended June 30, 2020 and 2019, the Company recorded a discrete tax benefit of $6.6 million and $3.2 million, respectively, primarily due to activity associated with equity awards. For the three months ended June 30, 2020 and 2019, the Company recorded a discrete tax benefit of $3.4 million and $1.4 million, respectively, primarily due to activity associated with equity awards. As of June 30, 2020 and December 31, 2019, the Company had deferred tax assets of $22.3 million and $13.4 million, respectively, which are included in other assets.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Net income (loss) per share

6 Months Ended

Jun. 30, 2020

Earnings Per Share [Abstract]

Net income (loss) per share

The following table presents the calculation of basic and diluted net income (loss) per share:



	Three Months Ended June 30,					Six Months Ended June 30,
	2020		2019			2020		2019
Numerator:
Net income (loss)	$	92.7	$	(9.5	)	$	80.2	$	(35.6	)

Denominator:
Weighted-average number of shares—basic	52.6		51.5			52.3		51.3
Dilutive securities—equity awards	0.9		—			0.9		—
Weighted-average number of shares—diluted	53.5		51.5			53.2		51.3

Net income (loss) per share - basic	$	1.76	$	(0.18	)	$	1.53	$	(0.69	)
Net income (loss) per share - diluted	$	1.73	$	(0.18	)	$	1.51	$	(0.69	)

Basic net income (loss) per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period,

adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive.

The following table presents the share-based awards that are not considered in the diluted net income (loss) per share calculation because the exercise price of the awards was greater than the average per share closing price during the three and six months ended June 30, 2020 and 2019.



	Three Months Ended June 30,		Six Months Ended June 30,
	2020	2019	2020	2019
Anti-dilutive stock awards	0.4	3.0	0.6	3.0

Stock-based compensation

6 Months Ended

Jun. 30, 2020

Stockholders' Equity Note [Abstract]

Stock-based compensation

During the six months ended June 30, 2020, the Company granted stock options to purchase 0.4 million shares of common stock and 0.8 million restricted and performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. Typically, the stock option and restricted stock unit grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the three-year performance period based on the Company's results compared to the performance criteria. During the three months ended June 30, 2020, the Company issued a broad-based fully vested equity award of approximately 0.2 million shares to employees below the senior vice president level that was valued at $14.7 million and is recorded as share-based compensation expense for the period ended June 30, 2020.

Stock-based compensation expense was recorded in the following financial statement line items:



	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Cost of product sales and contract development and manufacturing services	$	8.1	$	0.6	$	8.8	$	1.4
Research and development	5.4		1.0		6.3		2.1
Selling, general and administrative	10.9		6.5		15.9		11.4
Total stock-based compensation expense	$	24.4	$	8.1	$	31.0	$	14.9

Commitments and contingencies	6 Months Ended
Commitments and contingencies	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies ANDA Litigation - Perrigo 4mg On September 14, 2018, Adapt Pharma Inc., Adapt Pharma Operations Limited and Adapt Pharma Ltd. (collectively, "Adapt Pharma"), and Opiant Pharmaceuticals, Inc. ("Opiant"), received notice from Perrigo UK FINCO Limited Partnership ("Perrigo"), that Perrigo had filed an Abbreviated New Drug Application ("ANDA"), with the United States Food and Drug Administration seeking regulatory approval to market a generic version of NARCAN®(naloxone hydrochloride) Nasal Spray 4mg/spray before the expiration of U.S. Patent Nos. 9,211,253, (the "‘253 Patent"), 9,468,747 (the "‘747 Patent"), 9,561,177, (the "‘177 Patent"), 9,629,965, (the "‘965 Patent") and 9,775,838 (the "‘838 Patent"). On or about October 25, 2018, Perrigo sent a subsequent notice letter relating to U.S. Patent No. 10,085,937 (the "937 Patent"). Perrigo’s notice letters assert that its generic product will not infringe any valid and enforceable claim of these patents. On October 25, 2018, Emergent BioSolutions’ Adapt Pharma subsidiaries and Opiant, (collectively, the "Plaintiffs"), filed a complaint for patent infringement of the ‘253, ‘747, ‘177, ‘965, and the ‘838 Patents against Perrigo in the United States District Court for the District of New Jersey arising from Perrigo’s ANDA filing with the FDA. Plaintiffs filed a second complaint against Perrigo on December 7, 2018, for the infringement of the ‘937 Patent. On February 12, 2020, Adapt Pharma and Perrigo entered into a settlement agreement to resolve the ongoing litigation. Under the terms of the settlement, Perrigo has received a non-exclusive license under Adapt Pharma's patents to make, have made and market its generic naloxone hydrochloride nasal spray under its own ANDA. Perrigo’s license will be effective as of January 5, 2033 or earlier under certain circumstances including circumstances related to the outcome of the current litigation against Teva (as defined below) or litigation against future ANDA filers. The Perrigo settlement agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey. ANDA Litigation - Teva 2mg On or about February 27, 2018, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva Pharmaceuticals Industries Ltd. and Teva Pharmaceuticals USA, Inc. (collectively "Teva"), that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN® (naloxone hydrochloride) Nasal Spray 2 mg/spray before the expiration of U.S. Patent No. 9,480,644, (the "‘644 Patent"), and U.S. Patent No. 9,707,226, (the "'226 Patent"). Teva's notice letter asserts that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '644 Patent or the '226 Patent, or that the '644 Patent and '226 Patent are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey. The case is currently stayed pending the outcome of the appeal of the NARCAN® Nasal Spray 4 mg/spray case. ANDA Litigation - Teva 4mg On or about September 13, 2016, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN® (naloxone hydrochloride) Nasal Spray 4 mg/spray before the expiration of U.S. Patent No. 9,211,253 (the "'253 Patent"). Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received additional notices from Teva relating to the '747, the '177, the '965, the '838, and the ‘937 Patents. Teva's notice letters assert that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '253, the '747, the '177, the '965, the '838, or the ‘937 Patent, or that the '253, the '747, the '177, the '965, the '838, and the ‘937 Patents are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant also filed complaints for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '747, the '177, the '965, and the '838 Patents. All five proceedings have been consolidated. As of the date of this filing, Adapt Pharma Inc., Adapt Pharma Operations Limited, and Opiant, have not filed a complaint related to the ‘937 Patent. Closing arguments took place on February 26, 2020. In the complaints described in the paragraphs above, the Plaintiffs sought, among other relief, orders that the effective date of FDA approvals of the Teva ANDA products and the Perrigo ANDA product be a date not earlier than the expiration of the patents listed for each product, equitable relief enjoining Teva and Perrigo from making, using, offering to sell, selling, or importing the products that are the subject of Teva and Perrigo’s respective ANDAs, until after the expiration of the patents listed for each product, and monetary relief or other relief as deemed just and proper by the court. On June 5, 2020, the U.S. District Court for the District of New Jersey issued an unfavorable ruling against Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant in the consolidated case. Emergent has filed a Notice of Appeal (on July 23, 2020), after the U.S. District Court for New Jersey ruled June 5, 2020 in favor of Teva, and against Emergent and Opiant Pharmaceuticals Inc., Adapt Pharma's commercial partner, appealing the District Court decision to the Court of Appeals for the Federal Circuit. Emergent has filed suit in the Federal Court in Canada against Teva Pharmaceuticals (on July 23, 2020). The litigation in Canada is related to Teva Pharmaceuticals’ recent filing of an abbreviated new drug submission (ANDS) in Canada seeking to manufacture and sell a generic form of NARCAN® Nasal Spray ahead of the expiry of the Canadian patent covering our product. Emergent, through its Adapt subsidiaries, has filed suit within the prescribed time period following notice from Teva of its ANDS filing in Canada. Inter Partes Review (“IPR”) On or about February 19, 2019, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Nalox-1 Pharmaceuticals LLC that it had filed fifteen petitions for inter partes review of the '253 Patent, the '747 Patent, the '177 Patent, the '965 Patent, and the '838 Patent with the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office. Nalox-1’s petitions assert that each of the foregoing patents are invalid as obvious in view of prior art. Three of these petitions, IPR Nos. 2019-00685, 2019-00688, and 2019-00694, were instituted on August 27, 2019, September 9, 2019, and September 11, 2019, respectively. The oral hearing for the three instituted IPR proceedings was held before the PTAB on May 19, 2020. Adapt and Opiant remain committed to protect the intellectual property portfolio related to NARCAN®Nasal Spray.

Basis of Presentation and Principles of Consolidation (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of presentation	The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC. All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of June 30, 2020. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.
Fair value measurements	Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7 and Note 8).
Recently issued accounting standards	Recently Adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13") In June 2016, the FASB issued ASU 2016-13. ASU 2016-13 provides guidance on measurement of credit losses on financial instruments that changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans, and that requires entities to use a new, forward-looking “expected loss” model that is expected to generally result in the earlier recognition of allowances for losses. The guidance became effective for annual periods beginning after December 15, 2019, including interim periods within those years. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company's consolidated financial statements. ASU 2018-13, Fair Value Measurement - Disclosure Framework (Topic 820) ("ASU 2018-13") In August 2018, the FASB issued ASU 2018-13. ASU 2018-13 improves the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any removed or modified disclosures. The Company adopted the standard as of January 1, 2020 which has resulted in expanded disclosures around the Company's recurring level 3 fair value measurements. The disclosures are included in note 7 of the condensed consolidated financial statements. ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15") In August 2018, the FASB issued ASU 2018-15. ASU 2018-15 clarifies the accounting for implementation costs in cloud computing arrangements. ASU 2018-15 is effective for all entities for fiscal years beginning after December 15, 2019. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company's consolidated financial statements. ASU 2017-4, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-4") In January 2017, the FASB issued ASU 2017-4. ASU 2017-4 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-4 is effective for annual and interim goodwill tests beginning after December 15, 2019. The Company's measurement period is October 1. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption will not have a material impact on the Company's consolidation financial statements. Not Yet Adopted ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting In March 2020, the FASB issued Topic 848. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. ASC 848 contains optional expedients and exceptions for applying US GAAP to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. The Company continues to assess all potential impacts of the standard and will disclose the nature and reason for any elections that the Company makes. ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans ("ASU 2018-14") In August 2018, the FASB issued ASU 2018-14. ASU 2018-14 modifies the disclosure requirements for defined benefit pension plans and other post-retirement plans. ASU 2018-14 is effective for all entities for fiscal years ending after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-14 on its consolidated financial statements. ASU 2019-12, Simplifications to Accounting for Income Taxes ("ASU 2019-12") In December 2019, the FASB issued ASU 2019-12. ASU 2019-12 removes certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including deferred taxes for goodwill and allocating taxes for members of a consolidated group. ASU 2019-12 is effective for all entities for fiscal years beginning after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12 on its consolidated financial statements.

Inventories (Tables)

6 Months Ended

Jun. 30, 2020

Inventory Disclosure [Abstract]

Inventories

The components of inventory are as follows:



	June 30, 2020		December 31, 2019
Raw materials and supplies	$	81.7	$	70.5
Work-in-process	117.1		89.7
Finished goods	37.4		62.3
Total inventories	$	236.2	$	222.5

Property, plant and equipment (Tables)

6 Months Ended

Jun. 30, 2020

Property Plant and Equipment Income Statement Disclosures [Abstract]

Property, plant and equipment

Property, plant and equipment consisted of the following:



	June 30, 2020			December 31, 2019
Land and improvements	$	50.2		$	46.5
Buildings, building improvements and leasehold improvements	253.0			234.8
Furniture and equipment	342.6			334.2
Software	56.0			55.7
Construction-in-progress	112.7			81.5
Property, plant and equipment, gross	814.5			752.7
Accumulated depreciation	(234.4		)	(210.4		)
Total property, plant and equipment, net	$	580.1		$	542.3

Leases (Tables)

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Lease, Cost

The components of lease expense were as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Operating lease cost:
Amortization of right-of-use assets	$	1.0	$	0.7	$	2.1	$	1.3
Interest on lease liabilities	0.3		0.2		0.6		0.3
Total operating lease cost	$	1.3	$	0.9	$	2.7	$	1.6

Schedule of Leases Supplemental Balance Sheets

Supplemental balance sheet information related to leases was as follows:



(In millions, except lease term and discount rate)	Balance Sheet location	June 30, 2020			December 31, 2019
Operating lease right-of-use assets	Other assets	$	24.5		$	24.7

Operating lease liabilities, current portion	Other current liabilities	4.5			3.6
Operating lease liabilities	Other liabilities	21.6			22.1
Total operating lease liabilities		$	26.1		$	25.7

Operating leases:
Weighted average remaining lease term (years)		7.5			8.0
Weighted average discount rate		4.2		%	4.2		%

Intangible assets (Tables)

6 Months Ended

Jun. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

The following tables summarize the Company's intangible assets for the periods ended June 30, 2020 and December 31, 2019:



		June 30, 2020
(in millions)	Estimated Life	Cost		Additions		Accumulated Amortization		Net
Products	9-22 years	$	788.0	$	10.0	$	109.8	$	688.2
Customer relationships	8 years	28.6		—		24.7		3.9
Contract development and manufacturing	8 years	5.5		—		4.4		1.1
Total intangible assets		$	822.1	$	10.0	$	138.9	$	693.2



		December 31, 2019
(in millions)	Estimated Life	Cost		Accumulated Amortization		Net
Products	9-22 years	$	788.0	$	82.2	$	705.8
Customer relationships	8 years	28.6		23.0		$	5.6
Contract development and manufacturing	8 years	5.5		4.0		$	1.5
Total intangible assets		$	822.1	$	109.2	$	712.9

Contingent consideration (Tables)

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)

The following table is a reconciliation of the beginning and ending balance of contingent considerations and is based on level 3 significant unobservable inputs.




Balance at December 31, 2019	$	29.2
Change in fair value	1.1
Settlements	(1.1		)
Balance at June 30, 2020	$	29.2

Fair Value Measurement Inputs and Valuation Techniques

The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs:



Contingent Consideration Liability	Fair Value as of June 30, 2020	Valuation Technique	Unobservable Input	Range	Weighted Average
Revenue milestone and royalty based	$29.2 million	Discounted cash flow	Discount rate	2.5% - 8.6%	4.3%
			Probability of payment	10.0% - 40.0%	20.9%
			Projected year of payment	2020 - 2028	2022

Derivative instruments and hedging activities (Tables)

6 Months Ended

Jun. 30, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments

As of June 30, 2020, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:



	Number of Instruments	Notional
Interest rate swaps	7	$	350.0

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

The table below presents the fair value of the Company’s derivative financial instruments designated as hedges as well as their classification on the balance sheet.



Asset Derivatives							Liability Derivatives
	June 30, 2020			December 31, 2019			June 30, 2020			December 31, 2019
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Interest Rate Swaps	Other Current Assets	$	—	Other Current Assets	$	—	Other Current Liabilities	$	5.6	Other Current Liabilities	$	—
Interest Rate Swaps	Other Assets	$	—	Other Assets	$	—	Other Liabilities	$	11.9	Other Liabilities	$	2.0

Derivative Instruments, Gain (Loss)

The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income.



Hedging derivatives	Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative					Location of Gain or (Loss) Reclassified from Accumulated OCI into Income	Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income
Hedging derivatives	June 30,			December 31,			Six Months Ended June 30,
	2020			2019			2020			2019
Interest Rate Swaps	$	(17.5	)	$	2.0	Interest expense	$	(1.1	)	$	—

- Definition

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959

+ Details

Debt (Tables)

6 Months Ended

Jun. 30, 2020

Debt Disclosure [Abstract]

Schedule of Debt

The components of debt are as follows:



	June 30, 2020			December 31, 2019
Senior secured credit agreement - Term loan due 2023	$	430.3		$	435.9
Senior secured credit agreement - Revolver loan due 2023	353.0			373.0
2.875% Convertible Senior Notes due 2021	10.6			10.6
Other	3.0			3.0
Total debt	796.9			822.5
Current portion of long-term debt, net of debt issuance costs	(29.1		)	(12.9		)
Unamortized debt issuance costs	(9.7		)	(11.2		)
Non-current portion of debt	$	758.1		$	798.4

Revenue recognition (Tables)

6 Months Ended

Jun. 30, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The Company's revenues disaggregated by the major sources were as follows:



	Three Months Ended June 30, 2020						Three Months Ended June 30, 2019
	U.S. Government		Non-U.S. Government		Total		U.S. Government		Non-U.S. Government		Total
Product sales, net	$	224.2	$	74.3	$	298.5	$	94.6	$	88.9	$	183.5
Contract development and manufacturing services	44.6		28.0		72.6		—		18.7		18.7
Contracts and grants	20.7		2.9		23.6		38.3		2.7		41.0
Total revenues	$	289.5	$	105.2	$	394.7	$	132.9	$	110.3	$	243.2

	Six Months Ended June 30, 2020						Six Months Ended June 30, 2019
	U.S. Government		Non-U.S. Government		Total		U.S. Government		Non-U.S. Government		Total
Product sales, net	$	288.1	$	158.6	$	446.7	$	167.9	$	168.6	$	336.5
Contract development and manufacturing services	44.6		49.7		94.3		—		34.6		34.6
Contracts and grants	42.7		3.5		46.2		58.7		4.1		62.8
Total revenues	$	375.4	$	211.8	$	587.2	$	226.6	$	207.3	$	433.9

Rollforward of Contract Liabilities

The following table presents the rollforward of the contract liability balances:




December 31, 2019	$	88.9
Deferral of revenue	56.3
Revenue recognized	(27.2		)
June 30, 2020	$	118.0

Schedule of Accounts Receivable, Net

Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:



	June 30, 2020		December 31, 2019
Billed, net	$	202.2	$	227.3
Unbilled	56.4		43.4
Total, net	$	258.6	$	270.7

Net income (loss) per share (Tables)

6 Months Ended

Jun. 30, 2020

Earnings Per Share [Abstract]

Basic and Diluted Net Income per Share

The following table presents the calculation of basic and diluted net income (loss) per share:



	Three Months Ended June 30,					Six Months Ended June 30,
	2020		2019			2020		2019
Numerator:
Net income (loss)	$	92.7	$	(9.5	)	$	80.2	$	(35.6	)

Denominator:
Weighted-average number of shares—basic	52.6		51.5			52.3		51.3
Dilutive securities—equity awards	0.9		—			0.9		—
Weighted-average number of shares—diluted	53.5		51.5			53.2		51.3

Net income (loss) per share - basic	$	1.76	$	(0.18	)	$	1.53	$	(0.69	)
Net income (loss) per share - diluted	$	1.73	$	(0.18	)	$	1.51	$	(0.69	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share



	Three Months Ended June 30,		Six Months Ended June 30,
	2020	2019	2020	2019
Anti-dilutive stock awards	0.4	3.0	0.6	3.0

Stock-based compensation (Tables)

6 Months Ended

Jun. 30, 2020

Stockholders' Equity Note [Abstract]

Share-based Payment Arrangement, Expensed and Capitalized, Amount

Stock-based compensation expense was recorded in the following financial statement line items:



	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Cost of product sales and contract development and manufacturing services	$	8.1	$	0.6	$	8.8	$	1.4
Research and development	5.4		1.0		6.3		2.1
Selling, general and administrative	10.9		6.5		15.9		11.4
Total stock-based compensation expense	$	24.4	$	8.1	$	31.0	$	14.9

Business (Details)	6 Months Ended
Business (Details)	Jun. 30, 2020 category segment product
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of categories of public health threats \| category	5
Number of revenue generating products \| product	10
Number of operating segments \| segment	1

Basis of Presentation and Principles of Consolidation (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Money market funds	$ 178.7	$ 52.2

Inventories (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 81.7	$ 70.5
Work-in-process	117.1	89.7
Finished goods	37.4	62.3
Total inventories	$ 236.2	$ 222.5

Property, plant and equipment (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	$ 814.5	$ 752.7
Accumulated depreciation	(234.4)	(210.4)
Total property, plant and equipment, net	580.1	542.3
Land and improvements
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	50.2	46.5
Buildings, building improvements and leasehold improvements
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	253.0	234.8
Furniture and equipment
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	342.6	334.2
Software
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	56.0	55.7
Construction-in-progress
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	$ 112.7	$ 81.5

Leases - Narrative (Details)	6 Months Ended
Leases - Narrative (Details)	Jun. 30, 2020
Lessee, Lease, Description [Line Items]
Operating lease, renewal term	5 years
Operating lease, termination period	1 year
Minimum
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	1 year
Maximum
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	15 years

Leases - Components of Lease Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating lease cost:
Amortization of right-of-use assets	$ 1.0	$ 0.7	$ 2.1	$ 1.3
Interest on lease liabilities	0.3	0.2	0.6	0.3
Total operating lease cost	$ 1.3	$ 0.9	$ 2.7	$ 1.6

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Operating Leases
Operating lease right-of-use assets	$ 24.5	$ 24.7
Operating lease liabilities, current portion	4.5	3.6
Operating lease liabilities	21.6	22.1
Total operating lease liabilities	$ 26.1	$ 25.7
Operating leases:
Weighted average remaining lease term (years)	7 years 6 months	8 years
Operating leases:
Weighted average discount rate	4.20%	4.20%

Intangible assets - Schedule of Finite-lived Intangible Assets (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Cost
Intangible assets, gross	$ 822.1	$ 822.1
Finite-lived intangible assets acquired	10.0
Finite-lived intangible assets, accumulated amortization	138.9	109.2
Intangible assets, net	$ 693.2	$ 712.9
Minimum
Finite-Lived Intangible Assets [Line Items]
Amortization period of intangible asset	9 years	9 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Amortization period of intangible asset	22 years	22 years
Products
Cost
Intangible assets, gross	$ 788.0	$ 788.0
Finite-lived intangible assets acquired	10.0
Finite-lived intangible assets, accumulated amortization	109.8	82.2
Intangible assets, net	$ 688.2	$ 705.8
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Amortization period of intangible asset	8 years	8 years
Cost
Intangible assets, gross	$ 28.6	$ 28.6
Finite-lived intangible assets, accumulated amortization	24.7	23.0
Intangible assets, net	$ 3.9	$ 5.6
Contract development and manufacturing services
Finite-Lived Intangible Assets [Line Items]
Amortization period of intangible asset	8 years	8 years
Cost
Intangible assets, gross	$ 5.5	$ 5.5
Finite-lived intangible assets, accumulated amortization	4.4	4.0
Intangible assets, net	$ 1.1	$ 1.5

Intangible assets - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Business Acquisition [Line Items]
Amortization	$ 15.0	$ 14.7	$ 29.8	$ 29.2
Weighted average amortization period			13 years
Goodwill	$ 266.3		$ 266.3		$ 266.6
Raxibacumab
Business Acquisition [Line Items]
Change in amount of contingent consideration, liability			$ 10.0	$ 10.0

Contingent consideration (Details) $ in Millions	6 Months Ended
Contingent consideration (Details) $ in Millions	Jun. 30, 2020 USD ($)
Unobservable Input Reconciliation [Roll Forward]
Balance, beginning of period	$ 29.2
Change in fair value	1.1
Settlements	(1.1)
Balance, end of period	$ 29.2

Contingent consideration - Fair Value Level 3 of Significant Unobservable Inputs (Details) $ in Millions	Jun. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value	$ 29.2	$ 29.2
Discounted cash flow \| Fair Value, Inputs, Level 3 \| Fair Value, Recurring \| Discount rate \| Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business combination, contingent consideration, liability, measurement input	0.025
Discounted cash flow \| Fair Value, Inputs, Level 3 \| Fair Value, Recurring \| Discount rate \| Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business combination, contingent consideration, liability, measurement input	0.086
Discounted cash flow \| Fair Value, Inputs, Level 3 \| Fair Value, Recurring \| Discount rate \| Weighted Average
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business combination, contingent consideration, liability, measurement input	0.043
Discounted cash flow \| Fair Value, Inputs, Level 3 \| Fair Value, Recurring \| Probability of payment \| Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business combination, contingent consideration, liability, measurement input	0.100
Discounted cash flow \| Fair Value, Inputs, Level 3 \| Fair Value, Recurring \| Probability of payment \| Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business combination, contingent consideration, liability, measurement input	0.400
Discounted cash flow \| Fair Value, Inputs, Level 3 \| Fair Value, Recurring \| Probability of payment \| Weighted Average
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business combination, contingent consideration, liability, measurement input	0.209

Derivative instruments and hedging activities - Narrative (Details) $ in Millions	6 Months Ended
	Jun. 30, 2020 USD ($)
Interest rate swaps
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Net deferred losses from accumulated other comprehensive loss	$ 5.7

Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details) - Designated as Hedging Instrument - Interest rate swaps	Jun. 30, 2020 USD ($) instrument
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of Instruments \| instrument	7
Notional \| $	$ 350,000,000.0

Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details) - Interest rate swaps - Designated as Hedging Instrument - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Other Current Assets
Derivatives, Fair Value [Line Items]
Asset Derivatives	$ 0.0	$ 0.0
Other Assets
Derivatives, Fair Value [Line Items]
Asset Derivatives	0.0	0.0
Other Current Liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives	5.6	0.0
Other Liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives	$ 11.9	$ 2.0

Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details) - Interest rate swaps - USD ($) $ in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative	$ (17.5)		$ 2.0
Cash Flow Hedging \| Interest expense
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income	$ (1.1)	$ 0.0

Debt - Schedule (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019	Jan. 29, 2014
Debt Instrument [Line Items]
Long-term debt	$ 796.9	$ 822.5
Current portion of long-term debt, net of debt issuance costs	(29.1)	(12.9)
Unamortized debt issuance costs	(9.7)	(11.2)
Non-current portion of debt	758.1	798.4
2.875% Convertible Senior Notes due 2021
Debt Instrument [Line Items]
Long-term debt	$ 10.6	10.6
Stated percentage	2.875%		2.875%
Other
Debt Instrument [Line Items]
Long-term debt	$ 3.0	3.0
Senior secured credit agreement - Term loan due 2023
Debt Instrument [Line Items]
Long-term debt	430.3	435.9
Senior secured credit agreement - Revolver loan due 2023
Debt Instrument [Line Items]
Long-term debt	$ 353.0	$ 373.0

Debt - Narrative (Details)		1 Months Ended	6 Months Ended
Debt - Narrative (Details)	Oct. 15, 2018 USD ($)	Jun. 30, 2019	Jun. 30, 2020	Oct. 31, 2018 USD ($)	Jan. 29, 2014
Debt Instrument [Line Items]
Debt instrument, covenant, net leverage ratio rolling period		12 months
Debt instrument, covenant, net leverage ratio adjustment period		12 months
Amended Credit Agreement \| Minimum
Debt Instrument [Line Items]
Commitment fee percentage	0.15%
Amended Credit Agreement \| Maximum
Debt Instrument [Line Items]
Commitment fee percentage	0.30%
Amended Credit Agreement \| Eurocurrency
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.00%
Amended Credit Agreement \| Eurocurrency \| Minimum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.25%
Amended Credit Agreement \| Eurocurrency \| Maximum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	2.00%
Amended Credit Agreement \| Federal Funds Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.50%
Amended Credit Agreement \| Base Rate \| Minimum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.25%
Amended Credit Agreement \| Base Rate \| Maximum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.00%
2.875% Convertible Senior Notes due 2021
Debt Instrument [Line Items]
Stated percentage			2.875%		2.875%
Senior secured credit agreement - Revolver loan due 2023 \| 2017 Credit Agreement
Debt Instrument [Line Items]
Current borrowing capacity				$ 600,000,000
Senior secured credit agreement - Revolver loan due 2023 \| 2017 Credit Agreement \| Minimum
Debt Instrument [Line Items]
Debt covenant, consolidated debt service coverage ratio, minimum			2.50
Senior secured credit agreement - Revolver loan due 2023 \| 2017 Credit Agreement \| Maximum
Debt Instrument [Line Items]
Debt instrument, covenant, net leverage ratio through September 29, 2020			3.75
Debt instrument, covenant, net leverage ratio thereafter September 29, 2020			3.50
Debt instrument, covenant, net leverage ratio from October 1, 2019 to September 29, 2020			4.00
Senior secured credit agreement - Term loan due 2023 \| 2017 Credit Agreement
Debt Instrument [Line Items]
Current borrowing capacity				$ 450,000,000
Senior secured credit agreement - Term loan due 2023 \| Amended Credit Agreement
Debt Instrument [Line Items]
Percentage of original principal amount required to repay in the first two years	2.50%
Percentage of original principal amount required to repay during the third year	5.00%
Percentage of original principal amount required to repay remaining year	7.50%
Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right	$ 100,000,000

Revenue recognition - Narrative (Details) $ in Millions	6 Months Ended
Revenue recognition - Narrative (Details) $ in Millions	Jun. 30, 2020 USD ($) segment	Dec. 31, 2019 USD ($)
Revenue from Contract with Customer [Abstract]
Number of operating segments \| segment	1
Revenue, remaining performance obligation, amount	$ 1,400.0
Deferred costs, current	$ 40.6	$ 34.0

Revenue recognition - Remaining Performance Obligation (Details)	Jun. 30, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01
Revenue from Contract with Customer [Abstract]
Revenue, remaining performance obligation, expected timing of satisfaction, period	24 months

Revenue recognition - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue [Line Items]
Total revenues	$ 394.7	$ 243.2	$ 587.2	$ 433.9
U.S. Government
Disaggregation of Revenue [Line Items]
Total revenues	289.5	132.9	375.4	226.6
Non-U.S. Government
Disaggregation of Revenue [Line Items]
Total revenues	105.2	110.3	211.8	207.3
Product sales, net
Disaggregation of Revenue [Line Items]
Total revenues	298.5	183.5	446.7	336.5
Product sales, net \| U.S. Government
Disaggregation of Revenue [Line Items]
Total revenues	224.2	94.6	288.1	167.9
Product sales, net \| Non-U.S. Government
Disaggregation of Revenue [Line Items]
Total revenues	74.3	88.9	158.6	168.6
Contract development and manufacturing services
Disaggregation of Revenue [Line Items]
Total revenues	72.6	18.7	94.3	34.6
Contract development and manufacturing services \| U.S. Government
Disaggregation of Revenue [Line Items]
Total revenues	44.6	0.0	44.6	0.0
Contract development and manufacturing services \| Non-U.S. Government
Disaggregation of Revenue [Line Items]
Total revenues	28.0	18.7	49.7	34.6
Contracts and grants
Disaggregation of Revenue [Line Items]
Total revenues	23.6	41.0	46.2	62.8
Contracts and grants \| U.S. Government
Disaggregation of Revenue [Line Items]
Total revenues	20.7	38.3	42.7	58.7
Contracts and grants \| Non-U.S. Government
Disaggregation of Revenue [Line Items]
Total revenues	$ 2.9	$ 2.7	$ 3.5	$ 4.1

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Revenue recognition - Contract Liabilities (Details) $ in Millions	6 Months Ended
	Jun. 30, 2020 USD ($)
Change in Contract With Customer, Liability [Roll Forward]
Beginning of period	$ 88.9
Deferral of revenue	56.3
Revenue recognized	(27.2)
End of period	$ 118.0

Revenue recognition - Accounts Receivable (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Billed, net	$ 202.2	$ 227.3
Unbilled	56.4	43.4
Total, net	258.6	270.7
Allowance for doubtful accounts receivable	$ 0.5	$ 0.0

Income taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Income taxes (Details) - USD ($) $ in Millions	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Effective annual tax rate			26.00%	27.00%
Discrete tax benefit	$ 3.4	$ 1.4	$ 6.6	$ 3.2
Deferred tax assets, gross	$ 22.3		$ 22.3		$ 13.4

Net income (loss) per share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Numerator:
Net income (loss)	$ 92.7	$ (9.5)	$ 80.2	$ (35.6)
Denominator:
Weighted-average number of shares-basic (in shares)	52.6	51.5	52.3	51.3
Dilutive securities-equity awards (in shares)	0.9	0.0	0.9	0.0
Weighted-average number of shares-diluted (in shares)	53.5	51.5	53.2	51.3
Net income (loss) per share - basic (in dollars per share)	$ 1.76	$ (0.18)	$ 1.53	$ (0.69)
Net income (loss) per share - diluted (in dollars per share)	$ 1.73	$ (0.18)	$ 1.51	$ (0.69)
Antidilutive securities excluded from computation of earnings per share (in shares)	0.4	3.0	0.6	3.0

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Stock-based compensation - Narrative (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Stock issued or granted during period [Abstract]
Total stock-based compensation expense	$ 24.4	$ 8.1	$ 31.0	$ 14.9
Stock Options
Stock issued or granted during period [Abstract]
Stock options granted (in shares)			0.4
Award vesting period			3 years
Restricted Stock Units
Stock issued or granted during period [Abstract]
Restricted stock units granted (in shares)			0.8
Award vesting period			3 years
Equity Based Award
Stock issued or granted during period [Abstract]
Shares issued, share-based payment arrangement (in shares)			0.2
Total stock-based compensation expense			$ 14.7
Tranche One \| Stock Options
Stock issued or granted during period [Abstract]
Award vesting rights, percentage			33.33%
Tranche One \| Restricted Stock Units
Stock issued or granted during period [Abstract]
Award vesting rights, percentage			33.33%
Tranche Two \| Stock Options
Stock issued or granted during period [Abstract]
Award vesting rights, percentage			33.33%
Tranche Two \| Restricted Stock Units
Stock issued or granted during period [Abstract]
Award vesting rights, percentage			33.33%
Tranche Three \| Stock Options
Stock issued or granted during period [Abstract]
Award vesting rights, percentage			33.33%
Tranche Three \| Restricted Stock Units
Stock issued or granted during period [Abstract]
Award vesting rights, percentage			33.33%

Stock-based compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 24.4	$ 8.1	$ 31.0	$ 14.9
Cost of product sales and contract development and manufacturing services
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	8.1	0.6	8.8	1.4
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	5.4	1.0	6.3	2.1
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 10.9	$ 6.5	$ 15.9	$ 11.4